 |
Featuring a simply intelligence interface and substantial technological upgrades, the new multiplatform presents a new era in patient personalization
CAESAREA, Israel, March 26, 2025 /PRNewswire/ -- Alma Lasers, a Sisram Medical company and a global leader in energy-based medical and aesthetic solutions, announced today the global debut of the latest edition of its award-winning aesthetics platform, Alma Harmony. Built on a distinguished 20-year legacy, Alma's new platform features stunning modern design and substantial upgrades to offer more treatment possibilities and a simply intelligent experience.
Alma Harmony takes a huge leap forward in patient personalization. The new evolution is powered by the five of the most in-demand technologies, brilliantly integrated to provide a comprehensive range of treatments for almost any indication or skin type: the Q-Switch Laser stimulates collagen and treats pigmentation by targeting dermal layers, the Fractional Ablative laser creates pixel-sized perforations in the skin, inducing rejuvenation while preserving surrounding tissues for quicker recovery, Intense Pulsed Light (IPL) offers a balanced approach to aesthetic improvements across a wide range of patient skin types and concerns, Non-Ablative Lasers rejuvenate skin by promoting collagen production from within the dermis and the Green Diode Laser precisely treats vascular lesions, enhancing both efficacy and safety.
With up to a 45% increase in energy*, the new multiplatform offers the robust capabilities of standalone lasers in a single, sophisticated platform. This enhanced energy enables practitioners to address the diverse needs of patients—across different ages, skin types, and treatment goals—and to provide clinically proven treatments for the most in-demand categories, such as skin resurfacing, skin rejuvenation and tightening, hair removal, acne and acne scars, vascular lesions, pigmented lesions, and tattoo removal, to name a few.
Designed to enhance efficiency, simplicity, and ease of use, the new Alma Harmony includes advanced automated features such as customizable presets, ergonomically designed applicators, and functionality that makes operation seamless.
"The majority of the skin conditions we treat need more than one light or laser at the same time in the same session, and to work with a platform where you can have very easy connection enables us to do really personalized treatments with multiple wavelengths, multiple lights, to achieve the depth and the chromophore we want to target to achieve good results in those specific diseases" said Dr. Pablo Naranjo, MD, PhD, Medical Director of Elite Laser Clinic & Laser Unit at NISA Hospital, Madrid, Spain. "The new Alma Harmony allows me to have the same power as standalone lasers in an all-in-one platform and to achieve the next level of results with my patients" he added.
Recently, Alma Harmony won the European Product Design Award in the Healthcare category, recognized for its innovation and design excellence.
Lior Dayan, CEO of Alma, said: "After years of development, we are proud to introduce Alma Harmony to the global market. Combining cutting-edge technology with innovative design, every detail has been meticulously crafted to offer a seamless and intelligent user experience"
He added, "Alma Harmony sets a new standard for functionality, versatility, and performance. The new flagship multiplatform allows professionals to combine synergetic technologies to effectively treat a wide range of aesthetic concerns, addressing the growing consumer demand for combination procedures for longer-lasting results and a shorter recovery, while enhancing both practitioner efficiency and patient experience to unprecedented levels"
Aiming to support clinic business offerings and increase visibility, Alma is launching the new platform together with Harmony Bio-Boost, a branded treatment tackling today's most in-demand category—skin rejuvenation.
Harmony Bio-Boost, currently exclusive to Alma Harmony users, is a quick and effective treatment that harnesses the skin's natural healing process and leverages the power of bio stimulation to deliver enhanced results. This treatment enables improvement in skin tone and texture and serves as a catalyst for collagen renewal and elastin production that continues to work up to six months** post-treatment.
*Compared to Harmony XL PRO using specific parameters **After a non-ablative fractional laser treatment.
About Alma
Alma is a world-leading innovator in the aesthetic and surgical markets, offering holistic and cutting-edge solutions, including Laser, RF, Plasma, and Ultrasound technologies. We empower practitioners to deliver safe, effective, and life-transforming treatments using state-of-the-art, clinically proven solutions. For over two decades, Alma's award-winning products have set new standards in clinical excellence and innovation in the medical aesthetic industry. For more information, visit the company's website: almalasers.com
For media inquiries, please contact Alma PR team:
prglobal@almalasers.com
Featuring a simply intelligence interface and substantial technological upgrades, the new multiplatform presents a new era in patient personalization
CAESAREA, Israel, March 26, 2025 /PRNewswire/ -- Alma Lasers, a Sisram Medical company and a global leader in energy-based medical and aesthetic solutions, announced today the global debut of the latest edition of its award-winning aesthetics platform, Alma Harmony. Built on a distinguished 20-year legacy, Alma's new platform features stunning modern design and substantial upgrades to offer more treatment possibilities and a simply intelligent experience.
Alma Harmony takes a huge leap forward in patient personalization. The new evolution is powered by the five of the most in-demand technologies, brilliantly integrated to provide a comprehensive range of treatments for almost any indication or skin type: the Q-Switch Laser stimulates collagen and treats pigmentation by targeting dermal layers, the Fractional Ablative laser creates pixel-sized perforations in the skin, inducing rejuvenation while preserving surrounding tissues for quicker recovery, Intense Pulsed Light (IPL) offers a balanced approach to aesthetic improvements across a wide range of patient skin types and concerns, Non-Ablative Lasers rejuvenate skin by promoting collagen production from within the dermis and the Green Diode Laser precisely treats vascular lesions, enhancing both efficacy and safety.
With up to a 45% increase in energy*, the new multiplatform offers the robust capabilities of standalone lasers in a single, sophisticated platform. This enhanced energy enables practitioners to address the diverse needs of patients—across different ages, skin types, and treatment goals—and to provide clinically proven treatments for the most in-demand categories, such as skin resurfacing, skin rejuvenation and tightening, hair removal, acne and acne scars, vascular lesions, pigmented lesions, and tattoo removal, to name a few.
Designed to enhance efficiency, simplicity, and ease of use, the new Alma Harmony includes advanced automated features such as customizable presets, ergonomically designed applicators, and functionality that makes operation seamless.
"The majority of the skin conditions we treat need more than one light or laser at the same time in the same session, and to work with a platform where you can have very easy connection enables us to do really personalized treatments with multiple wavelengths, multiple lights, to achieve the depth and the chromophore we want to target to achieve good results in those specific diseases" said Dr. Pablo Naranjo, MD, PhD, Medical Director of Elite Laser Clinic & Laser Unit at NISA Hospital, Madrid, Spain. "The new Alma Harmony allows me to have the same power as standalone lasers in an all-in-one platform and to achieve the next level of results with my patients" he added.
Recently, Alma Harmony won the European Product Design Award in the Healthcare category, recognized for its innovation and design excellence.
Lior Dayan, CEO of Alma, said: "After years of development, we are proud to introduce Alma Harmony to the global market. Combining cutting-edge technology with innovative design, every detail has been meticulously crafted to offer a seamless and intelligent user experience"
He added, "Alma Harmony sets a new standard for functionality, versatility, and performance. The new flagship multiplatform allows professionals to combine synergetic technologies to effectively treat a wide range of aesthetic concerns, addressing the growing consumer demand for combination procedures for longer-lasting results and a shorter recovery, while enhancing both practitioner efficiency and patient experience to unprecedented levels"
Aiming to support clinic business offerings and increase visibility, Alma is launching the new platform together with Harmony Bio-Boost, a branded treatment tackling today's most in-demand category—skin rejuvenation.
Harmony Bio-Boost, currently exclusive to Alma Harmony users, is a quick and effective treatment that harnesses the skin's natural healing process and leverages the power of bio stimulation to deliver enhanced results. This treatment enables improvement in skin tone and texture and serves as a catalyst for collagen renewal and elastin production that continues to work up to six months** post-treatment.
*Compared to Harmony XL PRO using specific parameters **After a non-ablative fractional laser treatment.
About Alma
Alma is a world-leading innovator in the aesthetic and surgical markets, offering holistic and cutting-edge solutions, including Laser, RF, Plasma, and Ultrasound technologies. We empower practitioners to deliver safe, effective, and life-transforming treatments using state-of-the-art, clinically proven solutions. For over two decades, Alma's award-winning products have set new standards in clinical excellence and innovation in the medical aesthetic industry. For more information, visit the company's website: almalasers.com
For media inquiries, please contact Alma PR team:
prglobal@almalasers.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alma introduces Alma Harmony, a state-of-the-art aesthetic platform for next-level in-office treatments
Alma introduces Alma Harmony, a state-of-the-art aesthetic platform for next-level in-office treatments
Alma introduces Alma Harmony, a state-of-the-art aesthetic platform for next-level in-office treatments
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
